Evidence map›Paper›PMID 36711705›Full record

ArticlebioRxiv : the preprint server for biology2023

The QseB response regulator imparts tolerance to positively charged antibiotics by controlling metabolism and minor changes to LPS.

Melanie N Hurst, Connor J Beebout, Alexis Hollingsworth, Kirsten R Guckes, Alexandria Purcell, Tomas A Bermudez, Diamond Williams, Seth A Reasoner, M Stephen Trent, Maria Hadjifrangiskou

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Melanie N HurstDivision of Molecular Pathogenesis, Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Connor J BeeboutDivision of Molecular Pathogenesis, Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Alexis HollingsworthDepartment of Biological Sciences, Vanderbilt University, Nashville, TN, USA.
Kirsten R GuckesDivision of Molecular Pathogenesis, Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Alexandria PurcellDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602.
Tomas A BermudezDivision of Molecular Pathogenesis, Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Diamond WilliamsDepartment of Biological Sciences, Vanderbilt University, Nashville, TN, USA.
Seth A ReasonerDivision of Molecular Pathogenesis, Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
M Stephen TrentDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602.
Maria HadjifrangiskouDivision of Molecular Pathogenesis, Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Vanderbilt University Medical Center · USVanderbilt University · USUniversity of Georgia · US

Funding

pan-Genome of E.coli in the bladder and gut of women with recurrent UTIP50DK064540 · NIDDK · WASHINGTON UNIVERSITY · PI HULTGREN, SCOTT J. · 2002 to 2017
$17.9M
PATHOGENIC FIBER FORMATION IN BACTERIA: STRUCTURAL BASISR01AI048689 · NIAID · WASHINGTON UNIVERSITY · PI HULTGREN, SCOTT J. · 2001 to 2020
$7.6M
The Cell Envelope of the Multi-Drug Resistant Pathogen Acinetobacter baumanniiR01AI150098 · NIAID · UNIVERSITY OF GEORGIA · PI Michael Stephen Trent · 2020 to 2026
$3.9M
Development of a novel vaccine platform: Surface Antigen/Adjuvant Vaccine Engineering (SAAVE)R01AI129940 · NIAID · UNIVERSITY OF GEORGIA · PI TRENT, MICHAEL STEPHEN · 2017 to 2021
$3.3M
Molecular mechanisms required for the maintenance of the gram-negative outer membraneR01AI138576 · NIAID · UNIVERSITY OF GEORGIA · PI TRENT, MICHAEL STEPHEN · 2018 to 2022
$2.0M
Two-component system interactions as uropathogenic Escherichia coli drug targetsR01AI107052 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HADJIFRANGISKOU, MARIA · 2015 to 2019
$1.9M
The Vanderbilt Urologic Infection Repository, a Resource for Personalized Clinical DiscoveryP20DK123967 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CLAYTON, DOUGLASS BROOKS, HADJIFRANGISKOU, MARIA · 2019 to 2020
$680k
Elucidating the mechanisms of transient polymyxin resistance in pathogenic E. coli.F31AI143244 · NIAID · VANDERBILT UNIVERSITY · PI HURST, MELANIE N · 2019 to 2021
$85k
NIAID NIH HHS F31 AI143244NIAID NIH HHS R01 AI048689NIAID NIH HHS R01 AI107052NIAID NIH HHS R01 AI129940NIAID NIH HHS R01 AI138576NIAID NIH HHS R01 AI150098NIDDK NIH HHS P20 DK123967NIDDK NIH HHS P50 DK064540
6 · The paper itself

Abstract

The modification of lipopolysaccharide (LPS) in IMPORTANCE: Although antibiotic prescriptions are guided by well-established susceptibility testing methods, antibiotic treatments oftentimes fail. The presented work is significant, because it uncovers a mechanism by which bacteria transiently avoid killing by antibiotics. This mechanism involves two closely related transcription factors, PmrA and QseB, which are conserved across Enterobacteriaceae. We demonstrate that PmrA and QseB share regulatory targets in lipid A modification pathway and prove that QseB can orchestrate modifications of lipid A in

Identifiers

PMID36711705
PMCPMC9882033
OpenAlexW4315618819

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.